Stay updated on Magrolimab vs. Venetoclax in TP53 AML Clinical Trial

Sign up to get notified when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The clinical-trial record is now available, describing the magrolimab study, its results and study details, and noting that it was terminated for futility and is no longer recruiting.
    Difference
    100%
    Check dated 2026-11-13T13:14:41.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now shows revision v3.8.0 instead of v3.7.2; the study record remains inaccessible with a 403 Forbidden message.
    Difference
    0.2%
    Check dated 2026-10-30T14:08:16.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-23T13:56:58.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.1 to v3.7.2; the study page still displays a 403 error.
    Difference
    0.2%
    Check dated 2026-10-16T14:16:56.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1; the study record remains inaccessible behind a 403 error.
    Difference
    0.2%
    Check dated 2026-10-09T13:52:37.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error page instead of the study content, indicating an access/permission issue; as a result, users cannot view the study details on this page.
    Difference
    18%
    Check dated 2026-09-25T16:30:14.000Z thumbnail image

Stay in the know with updates to Magrolimab vs. Venetoclax in TP53 AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.